CYP3A5 and chronic kidney disease: In contrast, the influence of CYP3A5*3 pharmacogenetics was found to be lacking towards first-line antihypertensives for CKD, namely angiotensin converting enzyme inhibitor (ACEI) and angiotensin II blocker (ARB) [6].